Trial Search Results
Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease
Continuous deep brain stimulation (cDBS) is an established therapy for the major motor signs in Parkinson's disease. Currently, cDBS is limited to "open-loop" stimulation, without real-time adjustment to the patient's state of activity, fluctuations and types of motor symptoms, medication dosages, or neural markers of the disease. The purpose of this study is to determine if an adaptive DBS system, responding to patient specific, clinically relevant neural or kinematic feedback, is efficacious on the motor Unified Parkinson's Disease Rating Scale (UPDRS III) and specific phenotypic measures in Parkinson's Disease compared to OFF therapy (i.e., OFF DBS and withdrawn from medication) and more efficient than cDBS. Not every recruited participant completed every part of the protocol.
Stanford is currently not accepting patients for this trial.
- Device: Adaptive DBS (Activa PC+S Neurostimulator)
- Device: Continuous DBS (Activa PC+S Neurostimulator)
1. A diagnosis of idiopathic Parkinson's disease, with bilateral symptoms at Hoehn and
Yahr Stage greater than or equal to II.
2. Documented improvement in motor signs on versus off dopaminergic medication, with a
change in the Unified Parkinson's Disease Rating Scale motor (UPDRS III) score of >=
30% off to on medication.
3. The presence of complications of medication such as wearing off signs, fluctuating
responses and/or dyskinesias, and/or medication refractory tremor, and/or impairment
in the quality of life on or off medication due to these factors.
4. Subjects should be on stable doses of medications, which should remain unchanged until
the DBS system is activated. After the DBS system is optimized (during which time the
overall medication dose may be reduced to avoid discomfort and complications such as
dyskinesias) the medication dose should remain unchanged, if possible, for the
duration of the study.
5. Treatment with carbidopa/levodopa, and with a dopamine agonist at the maximal
tolerated doses as determined by a movement disorders neurologist.
6. Ability and willingness to return for study visits, at the initial programming and
after three, six and twelve months of DBS.
7. Age > 18
1. Subjects with significant cognitive impairment and/or dementia as determined by a
standardized neuropsychological battery.
2. Subjects with clinically active depression, defined according to the Diagnostic and
Statistical manual of Mental Disorders, Fourth Edition (DSM-IV) criteria and as scored
on a validated depression assessment scale.
3. Subjects with very advanced Parkinson's disease, Hoehn and Yahr stage 5 on medication
4. Age > 80.
5. Subjects with an implanted electronic device such as a neurostimulator, cardiac
pacemaker/defibrillator or medication pump.
6. Subjects, who are pregnant, are capable of becoming pregnant, or who are breast
7. Patients with cortical atrophy out of proportion to age or focal brain lesions that
could indicate a non-idiopathic movement disorder as determined by MRI
8. Subjects having a major comorbidity increasing the risk of surgery (prior stroke,
severe hypertension, severe diabetes, or need for chronic anticoagulation other than
9. Subjects having any prior intracranial surgery.
10. Subjects with a history of seizures.
11. Subjects, who are immunocompromised.
12. Subjects with an active infection.
13. Subjects, who require diathermy, electroconvulsive therapy (ECT), or transcranial
magnetic stimulation (TMS) to treat a chronic condition.
14. Subjects, who have an inability to comply with study follow-up visits.
15. Subjects, who are unable to understand or sign the informed consent
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study